Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.
Daver, N, Schlenk, RF, Russell, NH, Levis, MJ
Hassanein, M, Almahayni, MH, Ahmed, SO, Gaballa, S, El Fakih, R
Luskin, MR, Deangelo, DJ
Lim, SH, Dubielecka, PM, Raghunathan, VM
© 2021 Reactome